

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I declare that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Transforming Growth Factor Alpha HIII

the specification of which [] is attached hereto or [X] was filed on January 3, 1997 as Application Serial No. 08/778,545 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s):

			<u>Priority Claimed</u>	
			Yes	No
<u>None</u>				
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>		
			Yes	No
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>		

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:


60/011,136 (Provisional App. Serial No.)	Jan-04-96 (Filing Date)	Pending (Status: patented, pending, abandoned)
 (Application Serial No.)	 (Filing Date)	 (Status: patented, pending, abandoned)
 (Application Serial No.)	 (Filing Date)	 (Status: patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: John N. Bain (Reg. No. 18,651); John G. Gilfillan, III (Reg. No. 22,746); Elliot M. Olstein (Reg. No. 24,025); Raymond J. Lillie (Reg. No. 31,778); Charles J. Herron (Reg. No. 28,019); J. G. Mullins (Reg. No. 33,073), William Squire (Reg. No. 25,378) of Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, New Jersey 07068-1739; Robert H. Benson (Reg. No. 30,446) and A. Anders Brooks (Reg. No. 36,373), Paul C. Kimball (Reg. No. 34,610) of Human Genome Sciences, Inc. 9410 Key West Avenue, Rockville, Maryland, 20878.

CB Docket No. 325800-541
HGS Docket No. PF220

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole inventor: Ying-Fei Wei

Inventor's signature: 

Date: 3/26/87

Residence: 13524 Straw Bale Lane Darnestown, MD 20878

Citizenship: CN

Post Office Address: same as above

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Ying-Fei Wei

Attorney Docket No.: PF220

Application No.: 08/778,545

Art Unit: 1647

Filed: January 3, 1997

Examiner: Spector, L.

Title: Transforming Growth Factor Alpha HIII

**STATEMENT UNDER 37 C.F.R. § 3.73, REVOCATION OF PRIOR
POWERS OF ATTORNEY OR AUTHORIZATIONS OF AGENT, AND
POWER OF ATTORNEY OR AUTHORIZATION OF AGENT**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Statement Under 37 C.F.R. § 3.73

Human Genome Sciences, Inc., organized and existing under the laws of the State of Delaware, having its principal place of business at 9410 Key West Avenue, Rockville, Maryland 20850, states that it is the assignee of record of the entire right, title and interest for the above-identified application by virtue of an assignment from the inventor(s) of the above-identified application. The assignment was recorded in the U.S. Patent and Trademark Office on May 19, 1997 at Reel 8575, Frame 0690. A copy of the assignment is attached.

The undersigned, whose title is supplied below, is empowered to sign this document on behalf of the assignee. The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

Revocation of Prior Powers of Attorney or Authorizations of Agent

The assignee, Human Genome Sciences, Inc., hereby revokes all previous powers of attorney or authorizations of agent given in the above-captioned application.

Power of Attorney or Authorization of Agent

The assignee, Human Genome Sciences, Inc., hereby appoints the Practitioners at **Customer Number 22195** as its attorneys or agents with full power of substitution, association, and revocation to prosecute the application identified above, including any

continuation or divisional applications, and to transact all business in the U.S. Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to the above-mentioned Customer Number, namely **22195**. Please also change the Attorney Docket Number to that noted above, namely **PF220**.

On behalf of Human Genome Sciences, Inc.

For: Human Genome Sciences, Inc

Signature: James H. Davis

Name: James H. Davis, Ph.D.

Title: Senior Vice President, General Counsel, and Secretary

Date: 9 January 2003